Literature DB >> 1847609

Immunohistochemistry in the differential diagnosis of liver carcinomas.

J Hurlimann1, D Gardiol.   

Abstract

Immunohistochemical techniques were used to study 177 hepatic tumors (hepatocarcinoma, cholangiocarcinoma, hepatocholangiocarcinoma, adenocarcinoma of unknown origin, and metastatic carcinoma). Phenotypes suggestive of hepatocarcinoma included keratins 8 and 18, factor XIII a, alpha-fetoprotein. C-reactive protein, carcinoembryonic antigen (CEA) cross-reacting antigen; those in effect that excluded hepatocarcinoma were keratins 1, 5, 10, 11, 19, true CEA. C-reactive protein, used for the first time, proved to be a fairly sensitive and specific marker. Factor XIII a, which was thought to be synthesized only by histiocytes, was also present in hepatocytes. Immunohistochemistry appears to be an important tool in the diagnosis of hepatic tumors. As a result of this study, 32 cases were reclassified; several were found to be intermediate between hepatocarcinoma and cholangiocarcinoma. Sixteen cases apparently were true hepatocholangiocarcinomas. In 12 cases of hepatocarcinoma, some tumor cells expressed keratins of bile duct type. It was impossible to differentiate immunohistochemically cholangiocarcinoma from metastatic carcinoma, except in two cases with breast tissue markers.

Entities:  

Mesh:

Year:  1991        PMID: 1847609     DOI: 10.1097/00000478-199103000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

Review 2.  [Diagnosis and differential diagnosis of hepatocellular carcinoma].

Authors:  U Drebber; H P Dienes
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

3.  Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.

Authors:  C Röcken; J Licht; A Roessner; S Carl-McGrath
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

4.  Sigmoid colon metastasis from hepatocellular carcinoma.

Authors:  Dong Jun Yoo; Young Hwa Chung; Yoon Seon Lee; Sung Eun Kim; Young Joo Jin; Yu Mi Lee; Mi Jung Kim
Journal:  Korean J Hepatol       Date:  2010-12

5.  Liver metastasis with intraductal invasion originating from rectal cancer: report of a case.

Authors:  Hiroto Kayashima; Akinobu Taketomi; Yo-ichi Yamashita; Yousuke Kuroda; Dai Kitagawa; Norifumi Harimoto; Eiji Tsujita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2008-07-31       Impact factor: 2.549

6.  Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma.

Authors:  I Ariel; H Q Miao; X R Ji; T Schneider; D Roll; N de Groot; A Hochberg; S Ayesh
Journal:  Mol Pathol       Date:  1998-02

7.  Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase.

Authors:  P Fritz; E Behrle; P Beaune; M Eichelbaum; H K Kroemer
Journal:  Histochemistry       Date:  1993-06

8.  Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications.

Authors:  Madathilparambil V Suresh; Sanjay K Singh; Alok Agrawal
Journal:  J Biol Chem       Date:  2004-09-28       Impact factor: 5.157

9.  A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.

Authors:  Xiaoyong Fu; Lu Tan; Shuqin Liu; Honghai Li; Lei Chen; Jianmin Qin; Mengchao Wu; Hongyang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-19       Impact factor: 4.553

10.  A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis.

Authors:  Chang Kyun Hong; Jin Mo Yang; Bong Koo Kang; Jin Dong Kim; Young Chul Kim; U-Im Chang; Jin Young Yoo
Journal:  Korean J Intern Med       Date:  2007-12       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.